Fused imidazole derivatives as multidrug resistance modulators

A product containing

• a) a composition comprising a pharmaceutically effective amount of a compound of formula (I)
• a N-oxide form, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof, wherein
• the dotted line is an optional bond;
• n is 1 or 2;
• R1 is hydrogen;
• halo;
• formyl;
• C1-4alkyl;
• C1-4alkyl substituted with 1 or 2 substituents each independently selected from hydroxy, C1-4alkyloxy, C1-4alkylcarbonyloxy, imidazolyl, thiazolyl or oxazolyl;
• or a radical of formula
• —X—CO—OR5 (a-1);
• —X—CO—NR6R7 (a-2);
• or
• —X—CO—R10 (a-3);
• wherein
• —X— is a direct bond, C1-4alkanediyl or C2-6alkenediyl;
• R5 is hydrogen;
• C1-12alkyl;
• Ar;
• Het;
• C1-6alkyl substituted with C1-4alkyloxy, C1-4alkyloxycarbonylC1-4alkyloxy, Ar or Het;
• R6 and R7 each independently are hydrogen or C1-4alkyl;
• R10 is imidazolyl, thiazolyl or oxazolyl;
• R2 is hydrogen, halo, C1-4alkyl, hydroxyC1-4alkyl, C1-4alkyloxycarbonyl, carboxyl, formyl or phenyl;
• R3 is hydrogen, C1-4alkyl or C1-4alkyloxy;
• R4 is hydrogen, halo, C1-4alkyl, C1-4alkyloxy or haloC1-4alkyl;
• Z is Z1 or Z2;
• wherein
• Z1 is a bivalent radical of formula —CH2—, —CH2—CH2— or —CH═CH—;
• provided that when the dotted line is a bond, then Z1 is other than —CH2—;
• Z2 is a bivalent radical of formula —CHOH—CH2—, —O—CH2—, —C(═O)—CH2— or —C(═NOH)—CH2—;
• —A—B— is a bivalent radical of formula
• —Y—CR8═CH— (b-1);
• —CH═CR8—Y— (b-2);
• —CH═CR8—CH═CH— (b-3);
• —CH═CH—CR8═CH— (b-4);
• or
• —CH═CH—CH═CR8— (b-5);
• wherein
• each R8 independently is hydrogen, halo, C1-4alkyl, C1-4alkyloxy, hydroxyC1-4alkyl, hydroxycarbonylC1-4alkyl, formyl, carboxyl, ethenyl substituted with carboxyl, or ethenyl substituted with C1-4alkyloxycarbonyl;
• each Y independently is a bivalent radical of formula —O—, —S— or —NR9—;
• wherein R9 is hydrogen, C1-4alkyl or C1-4alkylcarbonyl;
• —A1— is a direct bond;
• C1-6alkanediyl;
• C1-6alkanediyl-oxy-C1-6alkanediyl;
• C1-6alkanediyloxy;
• carbonyl;
• C1-6alkanediylcarbonyl;
• C1-6alkanediyloxy substituted with hydroxy;
• or C1-6alkanediyl substituted with hydroxy or ═NOH;
• —A2— is a direct bond or C1-6alkanediyl;
• Q is phenyl;
• phenyl substituted with one or two substituents selected from hydrogen, hydroxy, C1-4alkyl, C1-4alkyloxy or haloC1-4alkyl;
• naphthalenyl;
• naphthalenyl substituted with one or two substituents selected from hydrogen, hydroxy, C1-4alkyl, C1-4alkyloxy or haloC1-4alkyl;
• pyridinyl;
• pyridinyl substituted with one or two substituents selected from hydrogen, hydroxy, C1-4alkyl, C1-4alkyloxy or haloC1-4alkyl;
• quinolinyl;
• or quinolinyl substituted with one or two substituents selected from hydrogen, hydroxy, C1-4alkyl, C1-4alkyloxy or haloC1-4alkyl;
• Ar is phenyl or phenyl substituted with 1, 2 or 3 substituents each independently selected from hydrogen, halo, C1-4alkyl or C1-4alkyloxy;
• Het is furanyl;
• furanyl substituted with C1-4alkyl, C1-4alkyloxy or hydroxyC1-4alkyl;
• oxazolyl;
• oxazolyl substituted with C1-4alkyl or C1-4alkyloxy;
• or quinolinyl
• and a pharmaceutically acceptable carrier;
• b) and a composition comprising a pharmaceutically effective amount of a pharmaceutical agent useful to treat conditions caused by pathogens and a pharmaceutically acceptable carrier, as a combined preparation for simultaneous, separate or sequential use in the treatment of conditions caused by pathogens.